『The Lancet Haematology in conversation with』のカバーアート

The Lancet Haematology in conversation with

The Lancet Haematology in conversation with

著者： The Lancet Group
無料で聴く

Lan-Lan Smith, Editor-in-Chief, Emma Cookson, Deputy Editor, and Daniela Marín, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to resuscitation with blood products compared with saline, the link between mental health and lymphoma to haemolytic disease in newborns, and more.© 2026 The Lancet Group 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Erdheim-Chester disease: a new international cohort study on phenotype, treatment, and determinants of prognosis

    Erdheim-Chester disease: a new international cohort study on phenotype, treatment, and determinants of prognosis
    2026/10/29

    Professor Julien Haroche and Professor Augusto Vaglio join us this month to discuss their new international cohort study describing phenotype, treatment, and determinants of prognosis in 1174 patients with Erdheim-Chester disease.

    Click here to read the full article:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00247-4/fulltext

    The Lancet Haematology in conversation with... is part of the Lancet Group podcast offering.

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.

    Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
    続きを読む 一部表示
    14 分
  • Thalassaemia revisited: from health burden to breakthroughs

    Thalassaemia revisited: from health burden to breakthroughs
    2026/10/06

    Thalassaemia care is advancing fast, from gene therapies to AI diagnostics, but access and prevention still lag behind. Hear from the authors of The Lancet Haematology's "Thalassaemia revisited: from health burden to breakthroughs" Series, produced with The Lancet Regional Health – Southeast Asia, on epidemiology across Asia, what's working in prevention, the real barriers to gene therapy access, and what's next for hydroxyurea, regional manufacturing, and AI in patient care.

    Click here to visit the series Hub page:

    www.thelancet.com/series-do/thalassaemia

    Or read the full articles from:

    The Lancet Regional Heath Southeast Asia: https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00148-4/fulltext and https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00095-8/fulltext

    The Lancet Haematology: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00173-0/fulltext and https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00197-3/fulltext

    The Lancet Haematology in conversation with... is part of the Lancet Group podcast offering.

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.

    Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
    続きを読む 一部表示
    48 分
  • Adverse event reporting in haematological malignancies with the authors of our Adverse Events Series

    Adverse event reporting in haematological malignancies with the authors of our Adverse Events Series
    2026/08/27

    Blood cancer treatments are advancing fast — but so are their side effects. Hear from the authors of The Lancet Haematology's Adverse Event reporting series on better trial design, patient-centric care, and what part 2 (2026) reveals about long-term toxicity, survivorship, regulation, and digital health tools.

    Click here to visit the series hub on thelancet.com:

    https://www.thelancet.com/series-do/adverse-events-in-haematology-oncology

    The Lancet Haematology in conversation with... is part of the Lancet Group podcast offering.

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.

    Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
    続きを読む 一部表示
    36 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません